Sensitization to the Cytotoxicity of Cisplatin by Transfection with Nucleotide Excision Repair Gene Xeroderma Pigmentosun Group A Antisense RNA in Human Lung Adenocarcinoma Cells

Clinical Cancer Research

Volumn 9, Issue 16 I, 2003, Pages 5874-5879

  Wu, Xiaoming ^a   Fan, Wei ^a   Xu, Shunqing ^a   Zhou, Yikai ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; CISPLATIN; COMPLEMENTARY RNA; DOXORUBICIN;

APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DNA REPAIR; DRUG SENSITIZATION; EXCISION REPAIR; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; LUNG ADENOCARCINOMA; NORTHERN BLOTTING; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; XERODERMA PIGMENTOSUM; XERODERMA PIGMENTOSUM GROUP A;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, NORTHERN; CELL DIVISION; CISPLATIN; DNA REPAIR; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; HUMANS; LUCIFERASES; LUNG NEOPLASMS; PLASMIDS; RNA, ANTISENSE; RNA, MESSENGER; TETRAZOLIUM SALTS; THIAZOLES; TRANSFECTION; TUMOR CELLS, CULTURED; XERODERMA PIGMENTOSUM; XERODERMA PIGMENTOSUM GROUP A PROTEIN;

EID: 0346103811     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Wood, R. D. DNA repair in eukaryotes. Annu. Rev. Biochem., 65: 135-167, 1996.
2. de Laat, W. L., Jaspers, N. G. J., and Hoeijmakers, J. H. J. Molecular mechanism of nucleotide excision repair. Genes Dev., 13: 768-785, 1999.
3. Tanaka, K., Miura, N., Satokata, I., Miyamoto, I., Yoshida, M. C., Satoh, Y., Kondo, S., Yasui, A., Okayama, H., and Okada, Y. Analysis of human excision repair gene involved in group A xeroderma pigmentosum and containing a zinc-finger domain. Nature (Lond.), 348: 73-76, 1990.
4. Jones, C. J., and Wood, R. D. Preferential binding of the xeroderma pigmentosum A complementing protein to damaged DNA. Biochemistry, 32: 12096-12104, 1993.
5. Tantin, D., Kansal, A., and Carey, M. Recruitment of putative transcription-repair coupling factor CSB/ERCC6 to RNA polymerase II elongation complexes. Mol. Cell. Biol., 17: 6803-6814, 1997.
6. Tantin, D. RNA polymerase II elongation complexes containing the Cockayne syndrome group B protein interact with a molecular complex containing the transcription factor IIH components xeroderma pigmentosum B and p62. J. Biol. Chem., 273: 27794-27799, 1998.
7. Selby, C. P., and Sancar, A. Human transcription-repair coupling factor CSB/ERCC6 is a DNA stimulated ATPase but is not a helicase and dose not disrupt the ternary transcription complex of stalled RNA polymerase II. J. Biol. Chem., 272: 1885-1890, 1997.
8. Johnes, J., Zhen, W., Reed, E., Parker, R. J., Sancar, A., and Bohr, V. A. Gene-specific formation and repair of cisplatin intrastrand adducts and interstrand cross-links in Chinese hamster ovary. J. Biol. Chem., 266: 7101-7107, 1991.
9. Sancar, A. Excision repair in mammalian cells. J. Biol. Chem., 270: 15915-15918, 1995.
10. Ferry, K. V., Hamilton, T. C., and Johnson, S. W. Increased nucleotide excision repair in cisplatin-resistant ovarian cancer cells: role of ERCC1-XPF. Biochem. Pharmacol., 60: 1305-1313, 2000.
11. Furuta, T., Ueda, T., Aune, G., Sarasin, A., Kraemer, K. H., and Pommier, Y. Transcription-coupled nucleotide excision repair as a determinant of cisplatin sensitivity of human cells. Cancer Res., 62: 4899-4902, 2002.
12. Damia, G., Imperatori, L., Stefanini, M., and D'Incalci, M. Sensitivity of CHO mutant cell lines with specific defects in nucleotide excision repair to different anti-cancer agents. Int. J. Cancer, 66: 779-783, 1996.
13. Aloyz, R., Xu, Z. Y., Bello, V., Bergeron, J., Han, F. Y., Yan, Y., Malapetsa, A., Alaoui-Jamali, M. A., Duncan, A. M., and Panasci, L. Regulation of cisplatin resistance and homologous recombinational repair by the TFIIH subunit XPD. Cancer Res., 62: 5457-5462, 2002.
14. Xu, Z., Chen, Z. P., Malapetsa, A., Alaoui-Jamali, M., Bergeron, J., Monks, A., Myers, T. G., Mohr, G., Sausville, E. A., Scudiero, D. A., Aloyz, R., and Panasci, L. C. DNA repair protein levels vis-a-vis anticancer drug resistance in the human tumor cell lines of the National Cancer Institute drug screening program. Anticancer Drugs, 13: 511-519, 2002.
15. Kartalou, M., and Essigmann, J. M. Mechanisms of resistance to cisplatin. Mutat. Res., 478: 23-43, 2001.
16. Rosenberg, E., Taher, M. M., Kuemmerle, N. B., Farnsworth, J., and Valerie, K. A truncated human xeroderma pigmentosum complementation group A protein expressed from an adenovirus sensitizes human tumor cells to ultraviolet light and cisplatin. Cancer Res., 61: 764-770, 2001.
17. O'Connor, P. M., Jackman, J., Bae, I., Myers, T. G., Fan, S., Mutoh, M., Scudiero, D. A., Sausville, E. A., Weinstein, J. N., Friend, S., Fornace, A. J., and Kohn, K. W. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res., 57: 4285-4300, 1997.
18. Fan, J., and Bertino, J. R. Modulation of cisplatinum cytotoxicity by p53: effect of p53-mediated apoptosis and DNA repair. Mol. Pharmacol., 56: 966-972, 1999.
19. Nicoletti, I., Migliorati, G., Pagliacci, M. C., Grignani, R., and Riccardi, C. A rapid and single method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J. Immunol. Methods, 139: 271-279, 1991.
20. Tewey, K. M., Chen, G. L., Nelson, E. M., and Liu, L. F. Intercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II. J. Biol. Chem., 259: 9182-9187, 1984.
21. Cummings, J., Anderson, L., Willmott, N., and Smyth, J. F. The molecular pharmacology of doxorubicin in vivo. Eur. J. Cancer, 27: 532-535, 1991.
22. Skladanowski, A., and Konopa, J. Relevance of interstrand DNA crosslinking induced by anthracyclines for their biological activity. Biochem. Pharmacol., 47: 2279-2287, 1994.
23. Gonzalez, V. M., Fuertes, M. A., Alonso, C., and Perez, J. M. Is cisplatin-induced cell death always produced by apoptosis? Mol. Pharmacol., 59: 657-663, 2001.
24. Eastman, A. The formation, isolation and characterization of DNA adducts produced by anticancer platinum complexes. Pharmacol. Ther., 34: 155-166, 1987.
25. Plooy, A. C., Fichtinger-Schepman, A. M., Schutte, H. H., van Dijk, M., and Lohman, P. H. The quantitative detection of various Pt-DNA-adducts in Chinese hamster ovary cells treated with cisplatin: application of immunochemical technique. Carcinogenesis (Lond.), 6: 561-566, 1985.
26. Fichtinger-Schepman, A. M., van der Veer, J. L., den Hartog, J. H., Lohman, P. H., and Reedijk, J. Adducts of the antitumor drug cisdiamminedichloroplatinum(II) with DNA: formation, identification, and quantitation. Biochemistry, 24: 707-713, 1985.
27. Lelland, L. R., Mistry, P., Abel, G., Loh, S. Y., O'Neill, C. F., Murrer, B. A., and Harrap, K. R. Mechanism-related circumvention of acquired cis-diamminedichloroplatinum(II) resistance using two pairs of human ovarian carcinoma cell lines by ammine/amine platinum(IV) dicarboxylates. Cancer Res., 52: 3857-3864, 1992.
28. Godwin, A. K., Meister, A., O'Dwyer, P. J., Huang, C. S., Hamilton, T. C., and Anderson, M. E. High resistance to cisplatin in human ovarian cancer cell lines is associated marked increase of glutathione synthesis. Proc. Natl. Acad. Sci. USA, 89: 3070-3074, 1992.
29. Johnson, S. W., Laub, P. B., Beesley, J. S., Ozols, R. F., and Hamilton, T. C. Increased platinum-DNA damage tolerance is associated with cisplatin resistance and cross-resistance to various chemotherapeutic agents in unrelated human ovarian cancer cell lines. Cancer Res., 57: 850-856, 1997.
30. Zhen, W., Link, C. J. Jr., O'Connor, P. M., Reed, E., Parker, R., Howell, S. B., and Bohr, V. A. Increased gene-specific repair of cisplatin interstrand cross-link in cisplatin-resistant human ovarian cancer cell lines. Mol. Cell. Biol., 12: 3689-3698, 1992.
31. Aebi, S., Kurdi-Haidar, B., Gordon, R., Cenni, B., Zheng, H., Fink, D., Christen, R. D., Boland, C. R., Koi, M., Fishel, R., and Howell, S. B. Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res., 56: 3087-3090, 1996.
32. Turchi, J. J., and Henkels, K. Human KU antoantigen binds cisplatin-damaged DNA but fails to stimulate human DNA-activated protein kinases. J. Biol. Chem., 271: 13861-13867, 1996.
33. Pil, P. M., and Lippard, S. J. Specific binding of chromosomal protein HMGI to DNA damaged by the anticancer drug cisplatin. Science (Wash. DC), 256: 234-237, 1992.
34. Zeng, R. N., Paterson, J., Alpert, L., Tsao, M. S., Viallet, J., and Alaoui-Jamali, M. A. Elevated DNA repair capacity is associated with intrinsic resistance of lung cancer to chemotherapy. Cancer Res., 55: 4760-4764, 1995.
35. Shellard, S. A., Fichtinger-Schepman, A. M. J., Lazo, J. S., and Hill, B. T. Evidence of differential cisplatin-DNA adduct formation, removal and tolerance of DNA damage in three human lung carcinoma cell lines. Anticancer Drugs, 4: 491-500, 1993.
36. Dabholkar, M., Vionnet, J., Bostick-Bruton, F., Yu, J. J., and Reed, E. Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy. J. Clin. Investig., 94: 703-708, 1994.
37. Dabholkar, M., Bostick-Bruston, F., Weber, C., Bohr, V. A., Egwuagu, C., and Reed, E. ERCC1 and ERCC2 expression in malignant tissues from ovarian cancer patients. J. Natl. Cancer Inst. (Bethesda), 84: 1512-1517, 1992.
38. Koberle, B., Masters, J. R., Hartley, J. A., and Wood, R. D. Defective repair of cisplatin-induced DNA damage caused by reduced XPA protein in testicular germ cell tumors. Curr. Biol., 9: 273-276, 1999.
39. Damia, G., Guidi, G., and D'Incalci, M. Expression of genes involved in nucleotide excision repair and sensitivity to cisplatin and melphalan in human cancer cell lines. Eur. J. Cancer, 34: 1783-1788, 1998.
40. Yang, L., Li, L., Jiang, H., Shen, Y., and Plunkett, W. Expression of ERCC1 antisense RNA abrogates gemcitabine-mediated cytotoxic synergism with cisplatin in human colon tumor cells defective in mismatch repair but proficient in nucleotide excision repair. Clin. Cancer Res., 6: 773-781, 2000.
41. Muotri, A. R., Marchetto, M. C., Suzuki, M. F., Okazaki, K., Lotfi, C. F., Brumatti, G., Amarante-Mendes, G. P., and Menck, C. F. Low amounts of the DNA repair XPA protein are sufficient to recover UV-resistance. Carcinogenesis (Lond.), 23: 1039-1046, 2002.
42. Cleaver, J. E., Charles, W. C., McDowell, M. L., Sadinski, W. J., and Mitchell, D. L. Overexpression of the XPA repair gene increase resistance to ultraviolet-radiation in human-cells by selective repair of DNA damage. Cancer Res., 55: 6152-6160, 1995.
43. Shen, H., Schultz, M., Kruh, G. D., and Tew, K. D. Increased expression of DNA-dependent protein kinase confers resistance to Adriamycin. Biochim. Biophys. Acta, 1381: 131-138, 1998.
44. Drummond, J. T., Anthoney, A., Brown, R., and Modrich, P. Cisplatin and Adriamycin resistance are associated with MutL α and mismatch repair deficiency in an ovarian tumor cell line. J. Biol. Chem., 271: 19645-19648, 1996.
45. Wilson, D. M., and Thompson, L. H. Life without DNA-repair. Proc. Natl. Acad. Sci. USA, 94: 12754-12757, 1997.
46. Klungland, A., Hoss, M., Gunz, D., Constantinou, A., Clarkson, S. G., and Doetsch, P. W. Base excision-repair of oxidative DNA damage activated by XPG protein. Mol. Cell, 3: 33-42, 1999.
47. Wang. X. W., Vermeulen, W., Coursen, J. D., Gibson, M., Lupold, S. E., Forrester, K., Xu, G., Elmore, L., Yeh, H., Hoeijmakers, J. H. J., and Harris, C. C. The XPB and XPD DNA helicases are components of the p53-mediated apoptosis pathway. Genes Dev., 10: 1219-1232, 1996.